{'fraction_non_alphanumeric': 0.03300733496332518, 'fraction_numerical': 0.03667481662591687, 'mean_word_length': 4.764084507042254, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MP66-13 TRAZODONE PRE-TREATMENT SCREENING AND SIDE EFFECTS COUNSELING AT A SINGLE VETERANS AFFAIRS HOSPITAL

We report results of our QA process on biopsy rates, comparing them to biopsy rates where MRI was done at centers not participating in QA. METHODS: Performance of fusion biopsy is restricted to 5 of our practice of 103 providers: 2098 patients were included in this study; 1294 and 804 for the QA and non-QA groups, respectively. Our QA process requires urologists and interpreting radiologists to sequentially cross-reference biopsy results to all MRI reads. Non-QA patients attended sites not participating in QA due to insurance reasons or patient personal preference. We assessed the positive biopsy rates for PI-RADS 4 and 5 lesions (P4/5) as well as the negative biopsy rates for Pi-RADS 3 lesions (P3). There was no financial relationship between IMP and any of the radiology centers. RESULTS: Negative biopsy rates for P3 between groups was not significantly different in any year. Positive biopsy rates for P4/5 in the QA group increased significantly from 45.5% to 66.3% between 2014 and 2018, respectively (p[0.003) while non-QA group P4/5 positive biopsy rates over the same interval increased nonsignificantly from 36.4% to 53.2% (p[0.07). No difference in positive or negative biopsy rates was noted between performing providers. By the third year of the QA process read accuracy was significantly greater in the QA group (Table 1). CONCLUSIONS: A standardized QA process significantly improves positive biopsy rates for P4/5 lesions over time, and should be instituted by all groups performing MRI fusion biopsy.